FDA Approves Expanded Use Of ENBREL ® (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis

First and Only Systemic Drug Approved in the U.S. to Treat Children Affected by This Serious Inflammatory Disease THOUSAND OAKS, Calif., Nov. 4, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of ENBREL® (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. "As many parents of children with moderate-to-severe plaque psoriasis can tell you, there is a need for FDA approved systemic therapies in the pediatric setting.  Until now, no biologics — w...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news